Clinical Trials Logo

Major Depressive Disorder clinical trials

View clinical trials related to Major Depressive Disorder.

Filter by:

NCT ID: NCT05633368 Completed - Covid-19 Clinical Trials

Impact of Covid-19 Pandemic on Patients Receiving Continuation or Maintenance Electroconvulsive Therapy

COVID-M-ECT
Start date: March 31, 2020
Phase:
Study type: Observational

Electroconvulsive therapy is a safe and effective therapeutic strategy in patients with treatment resistant depression. As relapse after successful ECT is significant even with adequate pharmacological strategies, continuation (up to 6 months after completion of index-ECT) or maintenance ECT (more than 6 months after index-ECT) is often necessary to maintain remission. During the current Covid-19 pandemic hospitals redirected resources and closed or significantly diminished ECT services. In this study we aim to assess the impact of discontinuing maintenance electroconvulsive therapy in patients diagnosed with unipolar depressive disorder.

NCT ID: NCT05615948 Completed - Clinical trials for Major Depressive Disorder

Oral Aspirin + Ketamine as Adjunct to Oral Antidepressant Therapy for Depression

Start date: December 6, 2022
Phase: Phase 4
Study type: Interventional

The purpose of this study is to assess the effects of simultaneous administration of oral aspirin and oral ketamine as a therapeutic for those with Treatment Resistant Depression.

NCT ID: NCT05597241 Completed - Clinical trials for Major Depressive Disorder

Multiple Ascending Dose and Electroencephalography Trial of GATE-202 in Healthy Volunteers

Start date: October 15, 2022
Phase: Phase 1
Study type: Interventional

To evaluate the safety, tolerability, pharmacokinetics and EEG pharmacodynamics of single and multiple ascending doses of apimostinel in normal human volunteers

NCT ID: NCT05553691 Completed - Clinical trials for Major Depressive Disorder

SPL026 With or Without SSRIs in Participants With MDD

Start date: December 13, 2022
Phase: Phase 1
Study type: Interventional

The main aim of the study is to test the safety and tolerability of single doses of SPL026 (N,N-dimethyltryptamine [DMT] fumarate, a psychedelic tryptamine) in patients currently taking a selective serotonin reuptake inhibitor (SSRI) for their depression, but for whom the SSRI is not fully relieving their depression.

NCT ID: NCT05535062 Completed - Clinical trials for Major Depressive Disorder

Study to Evaluate Treatment Effects Associated With the NeuroStar SoftStart Treatment Feature

Comfort Start
Start date: November 7, 2022
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the comfort of the NeuroStar® Advanced Therapy System regular prescribed TMS protocol versus a New Feature.

NCT ID: NCT05528718 Completed - Clinical trials for Major Depressive Disorder

SMILE Trial - Imaging Sub-Study

Start date: March 7, 2023
Phase:
Study type: Observational

This is a pilot sub-study of an ongoing trial comparing N2O to midazolam in MDD and will examine neuroimaging correlates of treatment response.

NCT ID: NCT05525390 Completed - Depression Clinical Trials

Extended Reality Behavioral Activation: An Intervention for Major Depressive Disorder

Start date: December 19, 2022
Phase: N/A
Study type: Interventional

The primary aims of this study are to assess the feasibility, acceptability, and tolerability of using an immersive extended reality (XR) headset to engage in behavioral activation (BA) for individuals diagnosed with major depressive disorder (MDD). The secondary aim of this study is to explore the efficacy of using XR to enhance BA therapy in a clinical MDD population.

NCT ID: NCT05524519 Completed - Clinical trials for Major Depressive Disorder

Intradermal Acupuncture Based on Changes in Biological Specificity of Acupoints for Major Depressive Disorder

Start date: January 1, 2022
Phase: N/A
Study type: Interventional

Acupoints are the stimulus points and reactive points for acupuncture to treat diseases. Therefore, this study is designed to detect the pain threshold and temperature of biological specificities of acupoints in healthy control (HC) participants and major depressive disorder (MDD) participants by using pressure pain threshold gauge (PTG) and infrared thermography (IRT). Based on the results of the PTG and IRT tests, the potentially superior acupoints for the treatment of MDD will be selected separately. Then, different acupoint groups selected based on different biological specificities tests will be used for clinical treatment to evaluate the clinical efficacy of intradermal acupuncture (IA) for MDD based on changes in the biological specificities of acupoints.

NCT ID: NCT05523076 Completed - Clinical trials for Major Depressive Disorder

Transdiagnostic Markers of Cognitive Symptoms in Disorders Affective.

Start date: March 15, 2018
Phase:
Study type: Observational

The objective of this project is to determine the concordance between the subjective and objective evaluation of cognitive functions in affective patients in partial remission through scales and cognitive tests that would be easily implemented in the different mental health care devices. This is a cross-sectional case-control study of non-probabilistic sampling, which will include a group of patients diagnosed with Major Depressive Disorder and Bipolar Disorder and a group of healthy controls from the same population and matched by age, gender and years of education with the group of patients. Patients will be recruited from the psychiatric service of the Hospital de la Santa Creu i Sant Pau who meet the inclusion criteria, and they will undergo a blood draw, a clinical assessment, a complete neuropsychological examination together with scales of subjective perception of cognitive deficit, a measure of cognitive reserve and an evaluation of psychosocial functionality. In addition, the same evaluation will be made to a group of healthy subjects.The total sample will be 120

NCT ID: NCT05516368 Completed - Clinical trials for Major Depressive Disorder

TF-CBT for Long-term PTSD, Major Depressive Disorder and Anxiety Disorders in Victims of Terrorism

Start date: March 2012
Phase: N/A
Study type: Interventional

The objective of this study is to test the efficacy of a Trauma-Focused Cognitive-Behavioural Therapy (TF-CBT) adapted for use with victims of terrorism in Spain who are diagnosed with posttraumatic stress disorder (PTSD), major depressive disorder and/or anxiety disorders subsequent to direct or indirect exposure to a series of terrorist attacks that occurred 20 years prior to treatment on average. Spanish victims who meet the criteria for long-term posttraumatic stress disorder, major depressive disorder, and/or anxiety disorders related to direct or indirect exposure to terrorist attacks that occurred 20 years ago, on average, will be randomly assigned to 16 weekly sessions of TF-CBT (experimental group) or waiting list control (control group) conditions. Between groups comparisons related to diagnostic rates and posttraumatic, depressive and anxiety symptoms will be made immediately after the intervention. Pre- follow-up comparisons related to diagnostic rates and posttraumatic, depressive, and anxiety symptoms will be carried out for the experimental group. It is hypothesised that participants receiving TF-CBT will have significantly lower diagnostic rates and mean levels of posttraumatic, depressive and anxiety symptoms than the control group immediately after the intervention, and that they will experience significant pre-treatment to 6-month follow-up decreases in diagnostic rates and in posttraumatic, depressive and anxiety symptoms.